Glenmark gets USFDA nod for generic Prograf Capsules
Advertisement
Mumbai: Glenmark Pharmaceuticals Inc., USA today announced that the company has been granted final approval by the United States Food & Drug Administration (USFDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg.
The product is a generic version of Prograf Capsules, 0.5 mg, 1 mg and 5 mg, of Astellas Pharm US, Inc.
According to IQVIA sales data for the 12 month period ending September 2020, the Prograf Capsules, 0.5 mg, 1 mg and 5 mg market achieved annual sales of approximately $286.8 million*.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.